The update covers all devices that claim an effect on body weight – from gastric balloons to neuromodulation systems. It applies across all key regulatory pathways, including PMA, 510(k), and De Novo, so this is a massive change of direction in how these products are evaluated.
In my opinion the most important change is in how effectiveness is assessed. The FDA used to allow more room in how results were interpreted and now it sets clear thresholds. For “weight loss,” devices need to show at least a 5% advantage over control in total body weight loss (TBWL). For “limited weight loss,” the threshold is 2%, while “weight management” may allow lower values if additional criteria are met. At the same time, at least 50% of patients must achieve a minimum 5% reduction in body weight, which limits the approval of devices with weaker performance.
Clinical trial requirements have also been tightened. The FDA points to randomized, double-blind studies, and where possible, the use of sham controls. Study duration is now directly tied to the indication – at least 12 months for “weight loss,” 6 to 12 months for “short-term weight loss,” and under 6 months only for “weight management.”
There are also new limits on how data can be collected. No more than 50% can come from outside the U.S., and a single site should not account for more than 20% of participants. That challenges the existing model, which often relied on lower-cost trials conducted abroad.
The agency is also expanding what counts as effectiveness. Weight loss on its own is no longer enough. Companies now need to show a clear, clinically meaningful impact on related conditions such as type 2 diabetes or hypertension.
Safety expectations have been significantly expanded as well. The guidance includes durability testing, simulations of gastrointestinal conditions, and detailed analysis of how materials degrade over time. For some devices, including gastric balloons, specific risks must be addressed, such as perforation or pancreatitis.
There is also a stronger focus on software and cybersecurity. If a device includes software, manufacturers need to document how it performs and how it is secured. In some cases, additional requirements for designated cyber devices will apply.
The new FDA guidance should translate into higher costs for manufacturers and longer timelines to get products to market. More complex trials, longer follow-up, and a greater share of U.S.-based data all raise the barrier to entry, especially for smaller companies.
From the patient perspective, these changes should ultimately improve the quality of available treatments. A stronger focus on long-term outcomes and real health benefits reduces the risk that devices with limited effectiveness or unclear safety profiles make it to market. It seems the FDA is trying to bring this segment closer to the standards already seen in pharmacological treatments. Companies will likely need to generate more robust data, which may slow down time to market – but it should also lead to safer, more reliable products, which is ultimately what matters most.